IHS Chemical Week

Regions :: Western Europe :: Switzerland

Daiichi Sankyo Signs Research and Commercial Agreement with BioWa and Lonza

12:36 AM MDT | July 26, 2010 | Deepti Ramesh

Lonza says that Daiichi Sankyo (Tokyo) has signed a research and commercial agreement with biotech company BioWa (Princeton, NJ), a subsidiary of Kyowa Hakko Kirin (Tokyo), and Lonza, to use their Potelligent CHOK1SV cell line for the development and production of recombinant antibodies. Potelligent CHOK1SV is a new host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System, which includes the cell line CHOK1SV. Potelligent CHOK1SV has been chosen...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa